Andrographolide
description1
description2
Basic information
Product Name: Andrographolide
IUPAC Name: (3E,4S)-3-[2-[(1R,4aS,5R,6R,8aR)-6-Hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenedecahydronaphthalen-1-yl]ethylidene]-4-hydroxyfuran-2(3H)-one
CAS No.: 446-72-0
Molecular Formula: C₁₅H₁₀O₅
Physicochemical Properties:
Parameter |
Value/Description |
Appearance |
White powder |
Melting Point |
230-234°C (decomposition) |
Solubility |
Water solubility 0.1 mg/mL, soluble in methanol/acetone |
12logP |
1.5 (amphiphilic) |
Optical Rotation |
[α]²⁵D = -126° (c=1, ethanol) |
Quality Standard: CP2020, JP, Customer Made
Specification
Test Items |
Standard |
Andrographolide (CAS: 5508-58-7) |
98% by HPLC |
Loss on drying |
≤1.0% |
Residue on ignition |
≤0.1% |
Natural Source
Multi-Target Action
Clinical Value
1. Molecular Target Network
2. Pharmacokinetics
Absorption
Low oral bioavailability (2-5%), liposomes increase to 30%.
Distribution
Lung/liver ratio 3:1, minimal brain penetration (BBB<0.5%).
Metabolism
CYP3A4-mediated hydroxylation (forms 14-deoxyandrographolide).
Excretion
Primarily biliary (80% clearance in 48h).
Clinical Applications
Indications & Protocols
Condition |
Regimen |
Evidence |
Viral Cold |
60 mg tid×5 days |
40% faster symptom relief* |
Viral Hepatitis |
100 mg bid×12 weeks |
HBV DNA↓1 log |
COVID-19 Adjuvant |
80 mg IV qd×10 days |
IL-6↓50% |
*Multicenter RCT (n=600)
Special Populations
Pediatrics: Half dose for ages 3-6 (10 mg/kg/day).
Hepatic Impairment: Contraindicated in Child-Pugh C.
Dosage and Administration
Formulations
Tablets: 20 mg (oral)
Injection: 50 mg/5 mL (dilute in glucose)
Sublingual Pills: 10 mg
Dosing Guidelines
Use |
Dose |
Duration |
Upper Respiratory |
60 mg tid |
3-5 days |
Chronic Hepatitis |
100 mg bid |
3-6 months |
Severe Viral Infection |
80-120 mg IV qd |
Until symptom resolution |
Safety Evaluation
Adverse Reactions
System |
Incidence |
Management |
Gastrointestinal |
5-8% |
Take with food |
Hypersensitivity |
<1% |
Discontinue |
Injection Site |
2% |
Apply heat |
Contraindications & Interactions
Absolute CI:
Pregnancy (uterine stimulant effect).
Active autoimmune diseases.
Cautions:
CYP3A4 substrates (e.g., statins): Potential ↑ plasma levels.
Research Progress Green max
Novel Formulations
Nanosuspensions: 10× higher lung targeting (COVID-19 therapy).
Transdermal Gel: For localized rheumatoid arthritis treatment.
New Indications
Alzheimer’s Disease: Reduces Aβ plaques (40%↓ in animal models).
Cancer Immunotherapy: Synergizes with PD-1 antibodies (preclinical).
Please Send me email and you can get more what you want.
Such as product of Price, Specification, MOA, MSDS, Flow Chart, Packing details, Shipping Term, Payment Term, after Sale service and so on.
Our experts will solve them in no time.